Pharma8k's (Page 5)

Arbutus Biopharma (ABUS) Discloses LNP Patent Litigation Updates, Notes $14.5 Billion Vaccine Sales

11 Dec 2025 SEC Filing 8-K Legal $ABUS

Arbutus Biopharma (ABUS) Discloses LNP Patent Litigation Updates, Notes $14.5 Billion Vaccine Sales

Arbutus Biopharma (ABUS) filed an 8-K detailing ongoing patent lawsuits against Moderna and Pfizer/BioNTech, citing $14.5 billion in global COVID-19 vaccine sales.

Centessa Pharmaceuticals (CNTA) Appoints New CEO, Advances Orexin Portfolio with ORX750 Phase 2a Data

11 Dec 2025 SEC Filing 8-K Leadership $CNTA

Centessa Pharmaceuticals (CNTA) Appoints New CEO, Advances Orexin Portfolio with ORX750 Phase 2a Data

Centessa Pharmaceuticals (CNTA) appointed Mario Alberto Accardi PhD as CEO effective January 1, 2026, and disclosed Phase 2a data for ORX750 in narcolepsy.

Rhythm Pharmaceuticals (RYTM) Reports Positive Phase 2 Data for Setmelanotide in Prader-Willi Syndrome

11 Dec 2025 SEC Filing 8-K Clinical Trials $RYTM

Rhythm Pharmaceuticals (RYTM) Reports Positive Phase 2 Data for Setmelanotide in Prader-Willi Syndrome

Rhythm Pharmaceuticals (RYTM) disclosed positive preliminary results from a Phase 2 trial of setmelanotide in Prader-Willi syndrome, with BMI reductions in 6 of 8 patients.

Roivant Sciences (ROIV) Reports Positive Phase 3 Data for Brepocitinib in Dermatomyositis, Plans NDA Filing in Early 2026

11 Dec 2025 SEC Filing 8-K $ROIV

Roivant Sciences (ROIV) Reports Positive Phase 3 Data for Brepocitinib in Dermatomyositis, Plans NDA Filing in Early 2026

Roivant Sciences (ROIV) disclosed positive Phase 3 data for brepocitinib in dermatomyositis and a $4.4 billion cash position in an SEC 8-K filing.

Alnylam Pharmaceuticals (ALNY) Repurchases $34.4 Million in Convertible Notes for $51.9 Million

11 Dec 2025 SEC Filing 8-K Financing $ALNY

Alnylam Pharmaceuticals (ALNY) Repurchases $34.4 Million in Convertible Notes for $51.9 Million

Alnylam Pharmaceuticals (ALNY) repurchased $34.4 million in convertible notes for $51.9 million, according to an SEC 8-K filing.